245 related articles for article (PubMed ID: 2434600)
1. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids.
Medof ME; Walter EI; Rutgers JL; Knowles DM; Nussenzweig V
J Exp Med; 1987 Mar; 165(3):848-64. PubMed ID: 2434600
[TBL] [Abstract][Full Text] [Related]
2. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland.
Lass JH; Walter EI; Burris TE; Grossniklaus HE; Roat MI; Skelnik DL; Needham L; Singer M; Medof ME
Invest Ophthalmol Vis Sci; 1990 Jun; 31(6):1136-48. PubMed ID: 1693916
[TBL] [Abstract][Full Text] [Related]
3. Decay accelerating factor of complement is anchored to cells by a C-terminal glycolipid.
Medof ME; Walter EI; Roberts WL; Haas R; Rosenberry TL
Biochemistry; 1986 Nov; 25(22):6740-7. PubMed ID: 2432921
[TBL] [Abstract][Full Text] [Related]
4. Isolation of two forms of decay-accelerating factor (DAF) from human urine.
Nakano Y; Sugita Y; Ishikawa Y; Choi NH; Tobe T; Tomita M
Biochim Biophys Acta; 1991 Jul; 1074(2):326-30. PubMed ID: 1712233
[TBL] [Abstract][Full Text] [Related]
5. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.
Davitz MA; Low MG; Nussenzweig V
J Exp Med; 1986 May; 163(5):1150-61. PubMed ID: 2422313
[TBL] [Abstract][Full Text] [Related]
6. Effect of glycoinositolphospholipid anchor lipid groups on functional properties of decay-accelerating factor protein in cells.
Walter EI; Ratnoff WD; Long KE; Kazura JW; Medof ME
J Biol Chem; 1992 Jan; 267(2):1245-52. PubMed ID: 1370460
[TBL] [Abstract][Full Text] [Related]
7. Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein (CD46) and decay accelerating factor (CD55).
Holmes CH; Simpson KL; Okada H; Okada N; Wainwright SD; Purcell DF; Houlihan JM
Eur J Immunol; 1992 Jun; 22(6):1579-85. PubMed ID: 1376264
[TBL] [Abstract][Full Text] [Related]
8. A high m.w. form of decay-accelerating factor (DAF-2) exhibits size abnormalities in paroxysmal nocturnal hemoglobinuria erythrocytes.
Kinoshita T; Rosenfeld SI; Nussenzweig V
J Immunol; 1987 May; 138(9):2994-8. PubMed ID: 2437202
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
[TBL] [Abstract][Full Text] [Related]
10. The influence of membrane components on regulation of alternative pathway activation by decay-accelerating factor.
Mold C; Walter EI; Medof ME
J Immunol; 1990 Dec; 145(11):3836-41. PubMed ID: 1700997
[TBL] [Abstract][Full Text] [Related]
11. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
[TBL] [Abstract][Full Text] [Related]
12. Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.
Koretz K; Brüderlein S; Henne C; Möller P
Br J Cancer; 1992 Nov; 66(5):810-4. PubMed ID: 1384641
[TBL] [Abstract][Full Text] [Related]
13. Isolation of decay accelerating factor (DAF) by a two-step procedure and determination of its N-terminal sequence.
Davitz MA; Schlesinger D; Nussenzweig V
J Immunol Methods; 1987 Feb; 97(1):71-6. PubMed ID: 2434569
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
Medof ME; Kinoshita T; Nussenzweig V
J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
[TBL] [Abstract][Full Text] [Related]
15. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF.
Telen MJ; Hall SE; Green AM; Moulds JJ; Rosse WF
J Exp Med; 1988 Jun; 167(6):1993-8. PubMed ID: 2455016
[TBL] [Abstract][Full Text] [Related]
16. Decay accelerating factor in guinea-pig reproductive organs.
He C; Nonaka M; Tada T; Koji T; Li W; Okada N; Okada H
Immunology; 2000 May; 100(1):91-8. PubMed ID: 10809964
[TBL] [Abstract][Full Text] [Related]
17. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.
Simpson KL; Jones A; Norman S; Holmes CH
Am J Pathol; 1997 Nov; 151(5):1455-67. PubMed ID: 9358772
[TBL] [Abstract][Full Text] [Related]
18. Decay-accelerating factor in human skin is associated with elastic fibers.
Werth VP; Ivanov IE; Nussenzweig V
J Invest Dermatol; 1988 Nov; 91(5):511-6. PubMed ID: 2459267
[TBL] [Abstract][Full Text] [Related]
19. Decay-accelerating factor (DAF) shares a common carbohydrate determinant with the variant surface glycoprotein (VSG) of the African Trypanosoma brucei.
Davitz MA; Gurnett AM; Low MG; Turner MJ; Nussenzweig V
J Immunol; 1987 Jan; 138(2):520-3. PubMed ID: 2432127
[TBL] [Abstract][Full Text] [Related]
20. Expression of decay-accelerating factor is reduced on hyperplastic synovial lining cells in rheumatoid synovitis.
Itoh J; Nose M; Fujita T; Kato M; Ohyama A; Kyogoku M
Clin Exp Immunol; 1991 Mar; 83(3):364-8. PubMed ID: 1706235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
